- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05370144
A Study Involving Neoadjuvant Chemoradiotherapy With Hypofractionated Radiotherapy in Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma
January 10, 2024 updated by: AHS Cancer Control Alberta
Phase II Study of Neoadjuvant Chemoradiotherapy With Hypofractionated Radiotherapy in Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma
An open-label, single-centre, non-randomized, Phase II trial in patients with esophageal adenocarcinoma.
This study aims to show that delivering hypofractionated neoadjuvant concurrent chemoradiotherapy is is equally effective as conventionally fractionated neoadjuvant concurrent chemoradiotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients with carcinoma of the esophagus or gastroesophageal junction who are suitable for curative intent trimodality therapy will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously weekly for 5 weeks.
External beam RT in 5 fractions over 1 week will be delivered any time between week 3-5 of chemotherapy.
Ideally patients should get radiotherapy during week 3 of chemotherapy but delivery during week 4-5 is permissible with documentation of the minor deviation.
RT must start within 30 calendar days of signing the informed consent form.
While restaging imaging is done as per institutional guidelines, ideally patients should get a PET/CT 6 weeks post chemoradiotherapy.
Patient will then go for esophagectomy 6-12 weeks after the completion of chemoradiotherapy, but ideally at 6-8 weeks post chemoradiotherapy.
Patients will be assessed for acute toxicity weekly during neoadjuvant therapy and then biweekly until esophagectomy.
One month after surgery, patient will have a final clinical follow up with the radiation oncologist and review any post-operative complications.
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amy Abel
- Phone Number: 403-476-2506
- Email: amy.abel@albertahealthservices.ca
Study Contact Backup
- Name: Sanjune Laurence Lee, MD
- Phone Number: 403-521-3164
- Email: Sangjune.Lee@albertahealthservices.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- Tom Baker Cancer Centre
-
Contact:
- Sangjune Lee, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Biopsy-proven invasive adenocarcinoma of the esophagus or GEJ (Siewart type I-II)
- Surgically resectable clinical stage T1N1-3 or T2-3N0-3 and no clinical evidence of metastatic spread are eligible (M0).
- Maximum length (based on best information available, with EGD preferred) and width of the tumor as seen on CT not exceeding 8 cm and 5 cm respectively.
- ECOG performance status ≤ 2
- Patient able to begin radiation treatment within 30 calendar days of signing the informed consent form.
- Age ≥ 18 and ≤ 75.
Adequate hematological, renal, hepatic and pulmonary function as defined by:
- Hemoglobin > 100 g/L
- Platelet count > 100x109/L
- Absolute neutrophil count > 1.5x109/L
- Total bilirubin ≤ 1.5x the upper limit of institutional normal
- Creatinine ≤ 120 µmol/L
- FEV1 ≥ 1.5 L
- Patients capable of childbearing are using adequate contraception.
- Written and informed consent of patient.
Exclusion Criteria:
- Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, or curatively treated carcinoma in situ of the cervix or a cured malignancy more than 5 years prior to enrollment
- Previous chemotherapy and radiotherapy
- New York heart Association Class III/IV and no history of active angina. Documented myocardial infarction within the 6 months preceding registration (pretreatment echocardiogram evidence of infarct only will not exclude patients). Patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure. History of 2nd or 3rd degree heart blocks
- Pre-existing motor or sensory neurotoxicity greater than WHO grade 1
- Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
- Dementia or altered mental status that would prohibit the understanding and giving of informed consent
- Weight loss > 20% within 3 months of the date of screening
- Esophageal stent
- Pregnant or lactating patients; women of childbearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of childbearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.
- Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.
- Unable to complete surveys in English without aid of interpreter.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypofractionated neoadjuvant concurrent chemoradiotherapy
Drug: Carboplatin and Taxol (paclitaxel) Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously for 5 weeks on Days 1,8,15,22 and 29. Radiation: Hypofractionated radiation |
Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the efficacy of delivering 5-fraction hypofractionated chemoradiotherapy
Time Frame: up to the Post-operative visit (60-90 days after surgery)
|
Tumor regression grades and pathological complete response rates determined after one week of surgery
|
up to the Post-operative visit (60-90 days after surgery)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the rates of acute toxicities
Time Frame: up to the Post-operative visit (60-90 days after surgery)
|
Safety will be determined by recording adverse events as per the CTCAE classification and grading system
|
up to the Post-operative visit (60-90 days after surgery)
|
To compare pathological response rates to changes in tumor FDG-PET uptake
Time Frame: At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
Changes in tumor FDG-PET standard uptake value and total lesion glycolysis
|
At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
To compare pathological response rates to changes in tumor dimensions
Time Frame: At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
Changes in tumor dimensions on CT
|
At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
To compare pathological response rates to dysphagia scores
Time Frame: up to the Post-operative visit (60-90 days after surgery)
|
Change in dysphagia score, measured at Screening/Baseline and at the Post-operative clinical follow-up
|
up to the Post-operative visit (60-90 days after surgery)
|
Correlate pre- and post-chemoradiation immune microenvironment composition with the above outcome variables (pathological response, dysphagia scores, changes in FDG-PET uptake and/or tumor dimensions on CT)
Time Frame: At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
Translational correlation between immune infiltration of biopsy and resection specimens with pathological (regression grades and response rates), clinical (dysphagia scores) and imaging (FDG-PET uptake and/or tumor dimensions on CT) outcomes
|
At the time of the re-staging scan (6 weeks post chemoradiotherapy).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 8, 2023
Primary Completion (Estimated)
February 3, 2027
Study Completion (Estimated)
February 3, 2028
Study Registration Dates
First Submitted
May 4, 2022
First Submitted That Met QC Criteria
May 6, 2022
First Posted (Actual)
May 11, 2022
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NACEA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
National Cancer Institute (NCI)RecruitingNeoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)United States
Clinical Trials on Hypofractionated radiotherapy
-
Maria Sklodowska-Curie National Research Institute...RecruitingRecurrent Soft Tissue Sarcoma | Recurrent Sarcoma | Radiation Induced Neoplasms | Radiation-Induced CancerPoland
-
Hospital da BaleiaUnknownBreast Cancer | Radiation Toxicity
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
University Hospital HeidelbergRecruitingProstate CancerGermany
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBreast CarcinomaChina
-
Medical University of GrazTerminatedProstate Cancer | Radiotherapy Side EffectAustria
-
Sunnybrook Health Sciences CentreCanadian Association of Radiation OncologyCompleted
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC...United States
-
Consorci Sanitari de TerrassaActive, not recruitingProstate Cancer | Faecal IncontinenceSpain